文献速递心脑血管急症消化、代谢与肾脏急症

临床实践中2型糖尿病患者使用SGLT2抑制剂的心血管风险

Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes.
PubMed 文献 · JAMA Netw Open · 2024-10-01
一句话结论在2型糖尿病临床实践中,与DPP4抑制剂相比,SGLT2抑制剂与总心血管疾病风险降低相关(HR 0.82),高危患者获益更明显。

这项回顾性队列研究利用台湾成功大学医院2015至2021年的电子病历,纳入8384例2型糖尿病患者,经倾向评分匹配后比较SGLT2抑制剂与DPP4抑制剂对总心血管事件的影响。结果显示SGLT2抑制剂与总心血管疾病风险降低相关(HR 0.82,95%CI 0.69-0.98),但对首次心血管事件无显著影响。在高危患者中获益更突出,如eGFR低于60 mL/min/1.73 m2者HR 0.70(95%CI 0.62-0.80)、有糖尿病相关并发症者HR 0.70(95%CI 0.64-0.78)、有心血管病史者HR 0.72(95%CI 0.65-0.80)。作者认为长期使用SGLT2抑制剂可能优化慢性心血管病患者的治疗获益,并鼓励优先用于高危患者。

要点

  • 在2型糖尿病临床实践中,SGLT2抑制剂与DPP4抑制剂相比,总心血管疾病风险降低(HR 0.82,95%CI 0.69-0.98)。
  • eGFR低于60 mL/min/1.73 m2者使用SGLT2抑制剂的总心血管风险HR 0.70(95%CI 0.62-0.80)。
  • 有糖尿病相关并发症者HR 0.70(95%CI 0.64-0.78),有心血管病史者HR 0.72(95%CI 0.65-0.80)。
  • 有心血管病史的女性亚组HR 0.59(95%CI 0.49-0.72),低于男性。

适用人群与场景

  • 2016至2019年首次启用研究药物的成人2型糖尿病患者,随访至多6年,数据来自台湾成功大学医院2015至2021年电子病历。
  • 倾向评分匹配后纳入1632对SGLT2抑制剂与DPP4抑制剂使用者。

研究设计与关键结果

  • 研究类型:回顾性队列研究,单中心(台湾成功大学医院),共8384例2型糖尿病患者,平均(SD)年龄63.7(12.4)岁,男性4645例(55.4%)。
  • 倾向评分匹配后SGLT2抑制剂组1632例(平均年龄57.8[12.0]岁;女性673例[41.2%],男性959例[58.8%]),DPP4抑制剂组1632例(平均年龄58.2[12.9]岁;女性655例[40.1%],男性977例[59.9%])。
  • 主要终点:SGLT2抑制剂与DPP4抑制剂相比,总心血管疾病复合事件风险降低(HR 0.82,95%CI 0.69-0.98),首次心血管事件无显著关联(原文未报告该比较的效应量)。
  • 高危亚组:eGFR低于60 mL/min/1.73 m2者HR 0.70(95%CI 0.62-0.80);有糖尿病相关并发症者HR 0.70(95%CI 0.64-0.78);有心血管病史者HR 0.72(95%CI 0.65-0.80)。
  • 性别亚组:在有心血管病史的高危患者中,女性HR 0.59(95%CI 0.49-0.72),低于男性。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,长期使用SGLT2抑制剂可能优化慢性心血管病患者的治疗获益。
  • 作者认为,SGLT2抑制剂在高心血管风险患者中的获益鼓励优先用于这些脆弱个体。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Cardiovascular disease (CVD) can be recurrent during type 2 diabetes (T2D) progression in this aging population. The effectiveness of sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy on total (ie, first and subsequent) CVD among patients with T2D in clinical practice remains uncertain.

OBJECTIVE: To analyze the comparative association of SGLT2i vs dipeptidyl peptidase 4 inhibitor (DPP4i) therapy with total CVD among patients with T2D in clinical practice.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used electronic medical records at the National Cheng Kung University Hospital, a leading medical center in Taiwan, from 2015 through 2021. Adult patients with T2D who initiated first use of the study drugs from 2016 through 2019, with up to 6 years of follow-up, were identified.

MAIN OUTCOMES AND MEASURES: The primary outcomes included total composite CVD events and individual CVD subtypes (ie, atrial fibrillation, coronary heart disease, heart failure, stroke, myocardial infarction, and transient ischemic attack). A shared frailty model analysis was used to assess the association of treatment with repeat CVD events. Data from patients at high risk for CVD recurrence were further analyzed. Data were analyzed from September 1, 2022, to December 31, 2023.

RESULTS: Overall, 8384 patients with T2D were identified (mean [SD] age, 63.7 [12.4] years; 4645 [55.4%] male). A total of 1632 propensity score-matched pairs of SGLT2i (mean [SD] age, 57.8 [12.0] years; 673 [41.2%] female and 959 [58.8%] male) and DPP4i (mean [SD] age, 58.2 [12.9] years; 655 [40.1%] female and 977 [59.9%] male) users were included. SGLT2i was associated with reduced total CVD risk vs DPP4i therapy (hazard ratio [HR], 0.82 [95% CI, 0.69-0.98]) but not the first CVD event (with the use of SGLT2i therapy were more prominent for patients at high risk of CVD (ie, HR, 0.70 [95% CI, 0.62-0.80] for individuals with estimated glomerular filtration rate lower than 60 mL/min/1.73 m2; HR, 0.70 [95% CI, 0.64-0.78]; for individuals having any diabetes-related complications; and HR, 0.72 [95% CI, 0.65-0.80] for individuals with a history of CVD) compared with the overall cohort. Among patients at high risk of CVD, greater reduced total CVD burden associated with SGLT2i therapy was observed for women vs men (eg, HR, 0.59 [95% CI, 0.49-0.72] in the subgroup with CVD history).

CONCLUSIONS AND RELEVANCE: In this cohort study of patients with T2D, the use of SGLT2is vs DPP4is was associated with reduced total cardiovascular burden, suggesting that long-term use of this therapy may optimize treatment benefit among patients with chronic CVD. The SGLT2i-associated benefit among patients with high risk of CVD encourages the prioritization of SGLT2i use for these vulnerable individuals.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Su HY, Yang CY, Lee YH, et al. Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes. JAMA Netw Open. 2024. PMID: 39476235. doi:10.1001/jamanetworkopen.2024.41765

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。